140 related articles for article (PubMed ID: 20804047)
21. Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell transplant in patients with Hodgkin's and non-Hodgkin's Lymphoma.
Gordan LN; Sugrue MW; Lynch JW; Williams KD; Khan SA; Moreb JS
Bone Marrow Transplant; 2003 Jun; 31(11):1009-13. PubMed ID: 12774052
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factor studies in Hodgkin's disease: problems and pitfalls.
Specht L
Leukemia; 1993 Nov; 7(11):1915-6; discussion 1917-9. PubMed ID: 8231263
[No Abstract] [Full Text] [Related]
23. Second malignant tumours in childhood Hodgkin's disease.
Jenkin D; Greenberg M; Fitzgerald A
Med Pediatr Oncol; 1996 Jun; 26(6):373-9. PubMed ID: 8614372
[TBL] [Abstract][Full Text] [Related]
24. Staging evaluation for patients with Hodgkin's disease. American College of Radiology. ACR Appropriateness Criteria.
Wolkov HB; Elman AJ; Hoppe RT; Pistenmaa DA; Mauch PM; Constine LS; Deming RL; Dosoretz DE; Prosnitz LR; Yahalom J; Chauvenet A; Connors JM; Glick JH; Leibel S
Radiology; 2000 Jun; 215 Suppl():1207-23. PubMed ID: 11037543
[No Abstract] [Full Text] [Related]
25. Patterns of treatment failure in pediatric and young adult patients with Hodgkin's disease: local disease control with combined-modality therapy.
Krasin MJ; Rai SN; Kun LE; Merchant TE; Metzger ML; Kaste SC; Howard SC; Hudson MM
J Clin Oncol; 2005 Nov; 23(33):8406-13. PubMed ID: 16293871
[TBL] [Abstract][Full Text] [Related]
26. Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients.
Brice P; Bastion Y; Divine M; Nedellec G; Ferrant A; Gabarre J; Reman O; Lepage E; Fermé C
Cancer; 1996 Sep; 78(6):1293-9. PubMed ID: 8826953
[TBL] [Abstract][Full Text] [Related]
27. Spleen involvement in Hodgkin's lymphoma: assessment and risk profile.
Rueffer U; Sieber M; Stemberg M; Gossmann A; Josting A; Koch T; Grotenhermen F; Diehl V;
Ann Hematol; 2003 Jul; 82(7):390-6. PubMed ID: 12764547
[TBL] [Abstract][Full Text] [Related]
28. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease.
Querellou S; Valette F; Bodet-Milin C; Oudoux A; Carlier T; Harousseau JL; Chatal JF; Couturier O
Ann Hematol; 2006 Nov; 85(11):759-67. PubMed ID: 16871391
[TBL] [Abstract][Full Text] [Related]
29. Late relapse after treatment for clinical stage I and II Hodgkin's disease.
Brierley JD; Rathmell AJ; Gospodarowicz MK; Sutcliffe SB; Pintillie M
Cancer; 1997 Apr; 79(7):1422-7. PubMed ID: 9083165
[TBL] [Abstract][Full Text] [Related]
30. Influence of biologic markers on the outcome of Hodgkin's lymphoma: a study by the Spanish Hodgkin's Lymphoma Study Group.
Montalbán C; García JF; Abraira V; González-Camacho L; Morente MM; Bello JL; Conde E; Cruz MA; García-Sanz R; García-Laraña J; Grande C; Llanos M; Martínez R; Flores E; Méndez M; Ponderós C; Rayón C; Sánchez-Godoy P; Zamora J; Piris MA;
J Clin Oncol; 2004 May; 22(9):1664-73. PubMed ID: 15117989
[TBL] [Abstract][Full Text] [Related]
31. Autologous stem cell transplantation for refractory and relapsed Hodgkin's disease: factors predictive of prolonged survival.
Burns LJ; Daniels KA; McGlave PB; Miller WJ; Ramsay NK; Kersey JH; Weisdorf DJ
Bone Marrow Transplant; 1995 Jul; 16(1):13-8. PubMed ID: 7581112
[TBL] [Abstract][Full Text] [Related]
32. Outcome in Hodgkin's disease: a 20-year cohort of patients.
Ranaghan L; Markey GM; Morris TC
Ulster Med J; 1998 Nov; 67(2):91-8. PubMed ID: 9885544
[TBL] [Abstract][Full Text] [Related]
33. State-of-the-art therapeutics: Hodgkin's lymphoma.
Connors JM
J Clin Oncol; 2005 Sep; 23(26):6400-8. PubMed ID: 16155026
[TBL] [Abstract][Full Text] [Related]
34. [A comparison of two risk-adapted regimens of therapy for Hodgkin's disease in children and adolescents].
Kuleva SA; Anishkin MIu; Kolygin BA
Vopr Onkol; 2008; 54(1):53-8. PubMed ID: 18416058
[TBL] [Abstract][Full Text] [Related]
35. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
[TBL] [Abstract][Full Text] [Related]
36. Definitive irradiation in the treatment of Hodgkin's disease. Analysis of outcome, prognostic factors, and long-term complications.
Sears JD; Greven KM; Ferree CR; D'Agostino RB
Cancer; 1997 Jan; 79(1):145-51. PubMed ID: 8988739
[TBL] [Abstract][Full Text] [Related]
37. [PROGNOSTIC RISK FACTORS FOR NEWLY DIAGNOSED PATIENTS WITH ADVANCED STAGES CLASSICAL HODGKIN'S LYMPHOMA].
Novosad OI; Kriachok IA; Grabovyy OM; Antonuk SA
Lik Sprava; 2014; (9-10):88-94. PubMed ID: 26492782
[TBL] [Abstract][Full Text] [Related]
38. Primary treatment of Hodgkin's disease.
Canellos GP
Ann Oncol; 2002; 13 Suppl 4():153-8. PubMed ID: 12401682
[No Abstract] [Full Text] [Related]
39. MET and MST1R as prognostic factors for classical Hodgkin's lymphoma.
Wha Koh Y; Park C; Hyun Yoon D; Suh C; Huh J
Mod Pathol; 2013 Sep; 26(9):1172-82. PubMed ID: 23558571
[TBL] [Abstract][Full Text] [Related]
40. [German Hodgkin's Lymphoma Study Group].
Ansén S; Engert A; Wolf J; Sieber M; Paulus U; Diehl V
Onkologie; 2001 Feb; 24 Suppl 1():35-48. PubMed ID: 11441310
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
